{"entity":{"id":"nct07765836","kind":"trial","name":"Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC","aka":["EKLAVYA-HRD"],"tldr":"A phase 2 trial of retifanlimab in pancreatic cancer, run by Massachusetts General Hospital, not yet recruiting.","summary":"Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC is a phase 2, interventional study registered as NCT07765836 by Massachusetts General Hospital, with a registry enrolment figure of 40 participants, started 2027-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: vilastobart (XTX101); Retifanlimab. Conditions listed: Pancreatic Cancer Metastatic. Primary outcome: Objective response rate (ORR). Pancreatic eligibility wording from the registry: \"* Participant must have histologically proven metastatic pancreatic cancer\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07765836","url":"https://clinicaltrials.gov/study/NCT07765836"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac","brca-palb2-pdac"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["retifanlimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07765836","phase":"2","setting":"A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)","sponsor":"Massachusetts General Hospital","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07765836/","neighbours":{"cancer":[{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"retifanlimab","kind":"drug","name":"Retifanlimab","route":"/drugs/retifanlimab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}